Liver transplantation in a patient with metastatic hepatocellular carcinoma after downstaging with single-agent immunotherapy: the first case report
Angelo Pirozzi, Mitesh J. Borad(Jacksonville College), Naohiro Okano(Kyorin University), Tanios Bekaii‐Saab(WinnMed), David M. Chascsa(National Institute of Diabetes and Digestive and Kidney Diseases), Sadeer Alzubaidi(Mayo Clinic in Arizona), Michelle Nguyen(Mayo Clinic in Arizona), Celine Hoyek(Mayo Clinic Hospital), Thomas Byrne(WinnMed), Oluseyi Abidoye(Mayo Clinic), Lorenza Rimassa(Humanitas University), Bashar Aqel(WinnMed)
Cited by 2
Related Papers
Clinical impact of COVID-19 on patients with cancer (CCC19): a cohort study
|The Lancet|2020|1.8k
Integrative Genomic Analysis of Cholangiocarcinoma Identifies Distinct IDH-Mutant Molecular Profiles
|Cell Reports|2017|619
Gemcitabine, Cisplatin, and nab-Paclitaxel for the Treatment of Advanced Biliary Tract Cancers
|JAMA Oncology|2019|472
Infigratinib (BGJ398) in previously treated patients with advanced or metastatic cholangiocarcinoma with FGFR2 fusions or rearrangements: mature results from a multicentre, open-label, single-arm, phase 2 study
|The Lancet. Gastroenterology & hepatology|2021|423